Did MEI/Kyowa Kirin Beat The PI3K Tolerability Trap?

Zandelisib Shows Unexpectedly Positive Data

 
• By Alaric DeArment

PI3K-delta inhibitors have often suffered from safety and tolerability issues, but Phase II data show higher efficacy and lower discontinuation rates for zandelisib than others in the class.

Snails on the athletic track moves the finish line (By Sergey Lavrentev. Shutterstock 463225937)
MEI/Kyowa Kirin's zandelisib appears to pull ahead of other PI3K-delta inhibitors on efficacy and safety • Source: Shutterstock

More from Anticancer

More from Therapy Areas